Browse FCGRT

Summary
SymbolFCGRT
NameFc fragment of IgG, receptor, transporter, alpha
Aliases FCRN; alpha-chain; FcRn alpha chain; IgG Fc fragment receptor transporter alpha chain; immunoglobulin recept ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein
Domain PF07654 Immunoglobulin C1-set domain
PF00129 Class I Histocompatibility antigen
Function

Binds to the Fc region of monomeric immunoglobulins gamma (PubMed:7964511, PubMed:10933786). Mediates the selective uptake of IgG from milk and helps newborn animals to acquire passive immunity. IgG in the milk is bound at the apical surface of the intestinal epithelium. The resultant FcRn-IgG complexes are transcytosed across the intestinal epithelium and IgG is released from FcRn into blood or tissue fluids (By similarity). Possible role in transfer of immunoglobulin G from mother to fetus (PubMed:7964511).

> Gene Ontology
 
Biological Process GO:0002414 immunoglobulin transcytosis in epithelial cells
GO:0002416 IgG immunoglobulin transcytosis in epithelial cells mediated by FcRn immunoglobulin receptor
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0019882 antigen processing and presentation
GO:0038093 Fc receptor signaling pathway
GO:0038094 Fc-gamma receptor signaling pathway
GO:0045056 transcytosis
Molecular Function GO:0003823 antigen binding
GO:0019763 immunoglobulin receptor activity
GO:0019770 IgG receptor activity
GO:0019864 IgG binding
GO:0019865 immunoglobulin binding
GO:0030881 beta-2-microglobulin binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolFCGRT
NameFc fragment of IgG, receptor, transporter, alpha
Aliases FCRN; alpha-chain; FcRn alpha chain; IgG Fc fragment receptor transporter alpha chain; immunoglobulin recept ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FCGRT and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between FCGRT and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
25221553colorectal carcinomaPromote immunity(T cell function)Therapeutically targeting the pathway by which FcRn enables T cell activation in response to IgG IC is thus a highly attractive prospect not only for the treatment of diseases that are driven by immune complexes but also for manipulating local immune responses against defined antigens such as those present during infections and cancer.
Summary
SymbolFCGRT
NameFc fragment of IgG, receptor, transporter, alpha
Aliases FCRN; alpha-chain; FcRn alpha chain; IgG Fc fragment receptor transporter alpha chain; immunoglobulin recept ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FCGRT in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFCGRT
NameFc fragment of IgG, receptor, transporter, alpha
Aliases FCRN; alpha-chain; FcRn alpha chain; IgG Fc fragment receptor transporter alpha chain; immunoglobulin recept ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FCGRT in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.5790.177
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.0620.71
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2380.917
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1240.756
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1650.946
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0720.981
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2110.648
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0770.966
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.4950.821
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5590.81
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4110.911
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3260.000574
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FCGRT in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFCGRT
NameFc fragment of IgG, receptor, transporter, alpha
Aliases FCRN; alpha-chain; FcRn alpha chain; IgG Fc fragment receptor transporter alpha chain; immunoglobulin recept ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FCGRT. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFCGRT
NameFc fragment of IgG, receptor, transporter, alpha
Aliases FCRN; alpha-chain; FcRn alpha chain; IgG Fc fragment receptor transporter alpha chain; immunoglobulin recept ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FCGRT. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FCGRT.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFCGRT
NameFc fragment of IgG, receptor, transporter, alpha
Aliases FCRN; alpha-chain; FcRn alpha chain; IgG Fc fragment receptor transporter alpha chain; immunoglobulin recept ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FCGRT. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFCGRT
NameFc fragment of IgG, receptor, transporter, alpha
Aliases FCRN; alpha-chain; FcRn alpha chain; IgG Fc fragment receptor transporter alpha chain; immunoglobulin recept ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FCGRT expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFCGRT
NameFc fragment of IgG, receptor, transporter, alpha
Aliases FCRN; alpha-chain; FcRn alpha chain; IgG Fc fragment receptor transporter alpha chain; immunoglobulin recept ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FCGRT and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFCGRT
NameFc fragment of IgG, receptor, transporter, alpha
Aliases FCRN; alpha-chain; FcRn alpha chain; IgG Fc fragment receptor transporter alpha chain; immunoglobulin recept ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FCGRT collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.